Cullinan Therapeutics (CGEM) Competitors $7.81 +0.05 (+0.64%) Closing price 01:00 PM EasternExtended Trading$7.80 -0.01 (-0.19%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. IRON, TARS, BEAM, CNTA, ARQT, ADPT, IMCR, SPRY, EWTX, and SDGRShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Disc Medicine (IRON), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. Its Competitors Disc Medicine Tarsus Pharmaceuticals Beam Therapeutics Centessa Pharmaceuticals Arcutis Biotherapeutics Adaptive Biotechnologies Immunocore ARS Pharmaceuticals Edgewise Therapeutics Schrodinger Cullinan Therapeutics (NASDAQ:CGEM) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations. Does the media prefer CGEM or IRON? In the previous week, Disc Medicine had 7 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 8 mentions for Disc Medicine and 1 mentions for Cullinan Therapeutics. Disc Medicine's average media sentiment score of 0.54 beat Cullinan Therapeutics' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CGEM or IRON? Cullinan Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 284.12%. Disc Medicine has a consensus price target of $96.70, indicating a potential upside of 76.64%. Given Cullinan Therapeutics' higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has better earnings & valuation, CGEM or IRON? Disc Medicine is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.68Disc MedicineN/AN/A-$109.36M-$3.92-13.97 Which has more risk & volatility, CGEM or IRON? Cullinan Therapeutics has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Do institutionals & insiders believe in CGEM or IRON? 86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 7.2% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 4.2% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is CGEM or IRON more profitable? Disc Medicine's return on equity of -22.61% beat Cullinan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -29.47% -28.19% Disc Medicine N/A -22.61%-21.07% SummaryDisc Medicine beats Cullinan Therapeutics on 9 of the 14 factors compared between the two stocks. Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$457.95M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-2.6821.5627.4020.04Price / SalesN/A281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book0.777.518.085.67Net Income-$167.38M-$55.05M$3.16B$248.47M7 Day Performance0.77%3.16%2.12%2.90%1 Month Performance-12.83%5.92%4.43%5.75%1 Year Performance-53.46%5.82%35.62%21.36% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics1.5362 of 5 stars$7.81+0.6%$30.00+284.1%-52.4%$457.95MN/A-2.6830Positive NewsGap UpIRONDisc Medicine3.0632 of 5 stars$51.68+0.1%$96.70+87.1%+27.8%$1.79BN/A-13.1830Analyst ForecastTARSTarsus Pharmaceuticals2.243 of 5 stars$40.60-0.1%$66.67+64.2%+46.8%$1.71B$182.95M-14.8750Positive NewsBEAMBeam Therapeutics2.3893 of 5 stars$16.71-0.3%$48.75+191.7%-11.9%$1.69B$63.52M-3.62510CNTACentessa Pharmaceuticals3.2155 of 5 stars$13.00+4.6%$27.89+114.5%+56.7%$1.66B$6.85M-7.18200ARQTArcutis Biotherapeutics2.0749 of 5 stars$14.40+4.2%$18.80+30.6%+48.0%$1.65B$196.54M-13.85150Positive NewsADPTAdaptive Biotechnologies3.4511 of 5 stars$10.56+1.7%$10.57+0.1%+240.7%$1.58B$178.96M-11.00790News CoverageGap UpIMCRImmunocore2.5334 of 5 stars$31.12-0.7%$58.89+89.2%-5.9%$1.57B$310.20M-72.37320SPRYARS Pharmaceuticals3.1082 of 5 stars$16.57+4.9%$31.00+87.1%+93.4%$1.55B$89.15M-103.5690Insider TradeEWTXEdgewise Therapeutics2.7247 of 5 stars$14.18-0.8%$39.78+180.5%-29.2%$1.50BN/A-9.1560News CoverageAnalyst ForecastAnalyst RevisionSDGRSchrodinger2.8416 of 5 stars$20.35-0.5%$32.80+61.2%+3.1%$1.50B$207.54M-7.74790News CoverageAnalyst Forecast Related Companies and Tools Related Companies IRON Alternatives TARS Alternatives BEAM Alternatives CNTA Alternatives ARQT Alternatives ADPT Alternatives IMCR Alternatives SPRY Alternatives EWTX Alternatives SDGR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
